摘要
目的 探讨非霍奇金淋巴瘤（NHL）患者淋巴瘤细胞中环氧合酶-2（COX-2）和乳腺癌耐药蛋白（BCRP）表达的相关性及其意义.方法 应用半定量反转录-聚合酶链式反应（RT-PCR）的方法,以β-actin作为内对照,检测61例NHL患者和10例反应增生性淋巴结患者（对照组）淋巴结组织的BCRP mRNA表达;应用免疫组织化学SP法对61例NHL患者和10例对照组淋巴结组织COX-2检测.结果 COX-2和BCRP在NHL中表达的阳性率分别为50.8%（31/61）和45.9%（28/61）,明显高于对照组（P＜0.05）.COX-2和BCRP在NHL中的表达呈正相关（χ^2=8.795,r=0.355,P＜0.05）.COX-2和BCRP在NHL中的表达与临床、病理因素,如年龄、性别、国际预后指数（IPI）、乳酸脱氢酶（LDH）、β2-微球蛋白及Ann Arbor分期等无明显相关性（P＞0.05）,但BCRP与化疗疗效明显相关.结论 BCRP可能在NHL多药耐药中发挥重要作用,有助于化疗疗效的评估及疾病预测;COX-2与NHL的多药耐药密切相关,COX-2抑制剂的使用,可能有助于提高患者对药物的敏感性.
Objective To investigate the correlation and significance of cyclooxygenase-2 （COX-2）and the breast cancer resistance protein （BCRP） expressions in non-Hodgkin lymphoma（NHL）. Methods Ten patients with reactive lymph nodes （RLN） were considered as a control group. Compared with β-actin as internal control, the BCRP mRNA expressions of 61 NHL samples and 10 lymph tissues in control group were detected by semi-quantitative revere transcription polymerase chain reaction （RT-PCR） assay, while the expressions of COX-2 protein of the above specimens were detected by SP immunohistochemistry. Results The positive rates of COX-2 and BCRP in NHL were 50.8 %（31/61） and 45.8 % （28/61）, respectively , and were higher than those in the control group （P 〈0.05）. The expression of COX-2 was statistically positive correlated to that of BCRP （χ^2=8.795, r=0.355, P〈0.05）. The expressions of COX-2 and BCRP were not correlated to clinical and pathological factors, such as age, sex, IPI, LDH, β2-microglobulin level and Ann Arbor stage, however, the expression of BCRP was statistically correlated to chemotherapy efficacy.Conclusion BCRP may be involved in multi-drug resistance （MDR） of NHL, so it may contribute to the assessment of chemotherapy and prediction of NHL. Since there is a strong correlation between COX-2 expression and MDR in NHL, the application of COX-2 inhibitors may enhance sensitivity of chemotherapy.
出处
《白血病．淋巴瘤》
CAS
2010年第8期483-485,共3页
Journal of Leukemia & Lymphoma
关键词
淋巴瘤
非霍奇金
抗药性
肿瘤
环氧合酶2
乳腺癌耐药蛋白
Lymphoma,non-Hodgkin
Drug resistance,neoplasms
Cyclooxygenase 2
Breast cancer resistance protein
